Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial()

BACKGROUND AND PURPOSE: Addition of carbogen and nicotinamide (hypoxia-modifying agents) to radiotherapy improves the survival of patients with high risk bladder cancer. The study investigated whether histopathological tumour features and putative hypoxia markers predicted benefit from hypoxia modif...

Descripción completa

Detalles Bibliográficos
Autores principales: Eustace, Amanda, Irlam, Joely J., Taylor, Janet, Denley, Helen, Agrawal, Shailesh, Choudhury, Ananya, Ryder, David, Ord, Jonathan J., Harris, Adrian L., Rojas, Ana M., Hoskin, Peter J., West, Catharine M.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Scientific Publishers 2013
Materias:
Phase III randomised trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885794/
https://www.ncbi.nlm.nih.gov/pubmed/23773411
http://dx.doi.org/10.1016/j.radonc.2013.05.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885794/
https://www.ncbi.nlm.nih.gov/pubmed/23773411
http://dx.doi.org/10.1016/j.radonc.2013.05.017

Ejemplares similares